IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Core Viewpoint - IGC Pharma, Inc. is enhancing its clinical trial execution and patient diversity for Alzheimer's disease by adding a new clinical site, Integrative Clinical Trials, LLC, to its Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease [1] Group 1: Company Developments - IGC Pharma, Inc. is a clinical-stage pharmaceutical company focused on developing innovative treatments for Alzheimer's disease using Artificial Intelligence [1] - The addition of Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site aims to strengthen the trial execution and improve patient diversity [1] Group 2: Clinical Trial Information - The Phase 2 CALMA clinical trial is specifically evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease [1] - Integrative Clinical Trials, LLC conducts studies across a broad range of Central Nervous System disorders, including Alzheimer's disease and mild cognitive impairment [1]